Related Experiment Video

Updated: Sep 28, 2026

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa

Mikko Kuoppamäki1, Ghassan Al-Barghouthy, Michael Jackson

  • 1Neurodegenerative Diseases Research Centre, King's College, London, United Kingdom.

Movement Disorders : Official Journal of the Movement Disorder Society
|December 5, 2002
PubMed

Insights

Parkinson's disease patients experience motor fluctuations with levodopa (L-dopa) treatment. MPTP-treated marmosets exhibit similar motor fluctuations, offering a valuable model for studying L-dopa complications.

Area of Science:

  • Neuroscience
  • Primate Models
  • Parkinson's Disease Research

Background:

  • Parkinson's disease (PD) patients often develop motor fluctuations after long-term levodopa (L-dopa) treatment.
  • Existing experimental models for investigating these L-dopa-induced motor complications are limited.

Purpose of the Study:

  • To investigate motor fluctuations in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets receiving repeated L-dopa administration.
  • To establish a nonhuman primate model for studying the pathophysiology of L-dopa treatment complications in Parkinson's disease.

Main Methods:

  • MPTP-treated common marmosets were administered L-dopa repeatedly.
  • Motor function, peak-dose dyskinesia, immobility, and dystonia were assessed during L-dopa treatment and withdrawal phases.
  • Motor performance was evaluated before L-dopa challenge, during L-dopa action, and during wearing-off and rebound periods.

Main Results:

  • All marmosets showed initial motor improvement with L-dopa but rapidly developed peak-dose dyskinesia.
  • Intermittent immobility was observed during L-dopa treatment.
  • Animals exhibited motor worsening before improvement after acute L-dopa challenge.
  • Rebound motor worsening below baseline occurred after L-dopa effects declined.
  • Leg dystonias were noted during wearing-off and rebound periods.

Conclusions:

  • MPTP-treated marmosets demonstrate a spectrum of motor fluctuations analogous to those seen in human Parkinson's disease patients on chronic L-dopa therapy.
  • This primate model provides a platform for investigating the underlying mechanisms of L-dopa-related motor complications.
  • Further research using this model can aid in developing strategies to manage treatment complications in Parkinson's disease.

More Related Videos

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...